Table 1 Demographics of the Sample (N = 70)
Age (mean [SD]) | 51.61 (10.34) | |
|---|---|---|
Ethnicity (%) | Hispanic or Latino | 3 (4) |
Not-Hispanic or Latino | 67 (96) | |
Race (%) | Black or African American | 21 (30) |
White | 49 (70) | |
Education (%) | Didn’t finish High School | 7 (10.0) |
High School Diploma | 8 (11) | |
Any education beyond High School | 55 (79) | |
Employment (%) | Disabled | 5 ( 7) |
Full-time | 38 (54) | |
Part-time | 5 ( 7) | |
Retired | 10 (14) | |
Student | 1 ( 1) | |
Unemployed | 11 (16) | |
Income (%) | Less than 15,000 | 11 (16) |
Between 15,000 and 29,999 | 5 ( 7) | |
Between 30,000 and 44,999 | 8 (11) | |
Between 45,000 and 59,999 | 7 (10) | |
Between 60,000 and 74,999 | 7 (10) | |
Between 75,000 and 89,999 | 10 (14) | |
Between 90,000 and 104,9999 | 8 (11) | |
Greater than or equal to 105,000 | 14 (20) | |
Marital Status (%) | Divorced/Separated | 14 (20) |
Married/Partner | 46 (66) | |
Single never married | 10 (14) | |
Hours of Sleep (mean (SD)) | 6.65 (1.57) | |
Menstrual Status (%) | Peri-menopausal | 6 (9) |
Post-menopausal | 40 (57) | |
Premenopausal | 24 (34) | |
Currently Smoking (%) | No | 57 (81) |
Yes | 13 (19) | |
Current ETOH (%) | No | 31 (44) |
Yes | 39 (56) | |
Weight (mean (SD)) | 171.87 (39.2) | |
Height (mean (SD)) | 63.48 (3.56) | |
BMI (mean (SD)) | 30.21 (7.56) | |
Grade (%) | 1 | 5 ( 7) |
2 | 28 (40) | |
3 | 37 (53) | |
Luminal A (%) | N | 33 (47) |
Y | 37 (53) | |
Luminal B (%) | N | 64 (91) |
Y | 6 ( 9) | |
Triple negative (%) | N | 50 (71) |
Y | 20 (29) | |
Estrogen receptor positive (%) | N | 29 (41) |
Y | 41 (59) | |
TX for ER (%) | Anastrozole, 1 mg, daily x 2years | 1 ( 1.5) |
Anastrozole, 1 mg, dailyx2years | 5 ( 7.7) | |
Arimidex 1 mg 1PO daily x 2 years | 2 ( 3.1) | |
Arimidex 1 mg 1PO daily x 5 years | 5 ( 7.7) | |
Arimidex 1 mg 1PO daily x 5years | 1 ( 1.5) | |
Femara 2.5 mg 1PO daily x 5 years | 2 ( 3.1) | |
Letrozole 2.5 mg 1PO daily x 5 years | 1 ( 1.5) | |
Letrozole 2.mg daily x 9 months | 1 ( 1.5) | |
None | 30 (46.2) | |
Tamoxifen 20 mg daily x 5 years | 1 ( 1.5) | |
Tamoxifen 20 mg 1PO daily x 5 years | 3 ( 4.6) | |
Tamoxifen 20 mg daily | 1 ( 1.5) | |
Tamoxifen 20 mg daily x 5 years | 5 ( 7.7) | |
Tamoxifen, 20 mg, daily x 10 years | 3 ( 4.6) | |
Tamoxifen, 20 mg, daily x 10 years | 1 ( 1.5) | |
Tamoxifen, 20 mg, daily x 5 years | 3 ( 4.6) | |
Progesterone Receptor positive (%) | N | 33 (47) |
Y | 37 (53) | |
HER2 pos (%) | N | 57 (81) |
Y | 13 (19) | |
HER2 pos ER/PR neg (%) | N | 63 (90) |
Y | 7 (10) | |
TX for HER pos (%) | 6 mg/kg every 3 weeks x1 year | 1 ( 1.4) |
Herceptin 2 mg/kg IV times 12 weeks to be followed by maintenance Herceptin for 1 year | 1 ( 1.4) | |
Herceptin 6 mg/kg IV q3 weeks x 1 year | 2 ( 2.9) | |
Herceptin 6 mg/kg every 3 weeks x 1 year | 4 ( 5.8) | |
Herceptin 6 mg/kg every 3 wks | 1 ( 1.4) | |
Herceptin 6 mg/kg every three weeks x 1 year | 2 ( 2.9) | |
Herceptin 6 mg/kg q3 weeks | 1 ( 1.4) | |
Herceptin 6 mg/kg q3 weeks x 1yr | 1 ( 1.4) | |
None | 56 (82.1) | |
Number of Lymph Pos (mean (SD)) | 0.96 (2.15) | |
Surgery (%) | Biopsy | 5 (7) |
Lumpectomy | 20 (29) | |
Segmental | 14 (20) | |
Simple | 30 (44) | |
Neoadjuvant (%) | N | 63 (90) |
Y | 7 (10) | |
Chemo Final (%) | AC | 2 ( 2.9) |
CMF | 2 ( 2.9) | |
TAC | 34 (48.6) | |
TC | 20 (28.6) | |
TCH | 12 (17.1) | |
Followed by Taxane (%) | N | 37 (55.2) |
Y | 30 (44.8) | |
Radiation TX (%) | N | 16 (22.9) |
Y | 54 (77.1) |